Compare MO HJR 73 (2025) and MO SJR 23 (2025)
The introduced text of these two bills, side by side, with the wording they share.
- MO HJR 73 (2025) · Missouri · 2025 · Enacted
- MO SJR 23 (2025) · Missouri · 2025 · Failed
186 shared 8-word phrases found in the introduced text of these two bills.
This highlights wording the two bills share in their introduced text. A shared passage may include text that both bills quote from the same existing law, not only language either one drafted. A match shows that the texts overlap; it does not show who drafted a bill, and filing order alone does not show which bill copied which.
| MO HJR 73 (2025) | MO SJR 23 (2025) |
|---|---|
| JOINT RESOLUTION NO. 73 103RD GENERAL ASSEMBLY INTRODUCED BY | JOINT RESOLUTION NO. 23 103RD GENERAL ASSEMBLY INTRODUCED BY |
| JOINT RESOLUTION Submitting to the qualified voters of Missouri an amendment | JOINT RESOLUTION Submitting to the qualified voters of Missouri, an amendment |
| relating to reproductive health care. Be it resolved by the | relating to reproductive health care. Be it resolved by the |
| concurring therein: That at the next general election to be held in the state of Missouri, on Tuesday next 2 following the first Monday in November, 2026, or at a special election to be called by the 3 governor for that purpose, there is hereby submitted to the qualified voters of this state, for 4 adoption or rejection, the following amendment to Article I of the Constitution of the state of 5 Missouri: Section A | concurring therein: That at the next general election to be held in the 1 state of Missouri, on Tuesday next following the first Monday 2 in November, 2026, or at a special election to be called by 3 the governor for that purpose, there is hereby submitted to 4 the qualified voters of this state, for adoption or 5 rejection, the following amendment to article I of the 6 Constitution of the state of Missouri: 7 Section A |
| to be known as Section 36(a), to read as follows: Section 36(a | to be known as section 36(a), 2 to read as follows: 3 Section 36(a |
| born with a medically 15 verifiable disorder of sex development or to treat any infection, injury, disease, or 16 disorder unrelated to the purpose of | born with a 26 medically-verifiable disorder of sex development or the 27 treatment of any infection, injury, disease, or disorder 28 unrelated to the purpose of |
| Gender transition surgery", a surgical procedure performed for the 32 purpose of assisting an individual with identifying with and living as a gender different 33 from his or her biological sex | Gender transition surgery", a surgical procedure 30 performed for the purpose of assisting an individual with 31 identifying with and living as a gender different from his 32 or her biological sex |
| based on reasonable medical 35 judgment, so complicates the medical condition of a pregnant woman as to necessitate 36 the immediate termination of her pregnancy to avert the death of the pregnant woman 37 or for which a delay will create a serious risk of substantial and irreversible physical 38 impairment of a major bodily function of the pregnant woman | based on 38 reasonable medical judgment, so complicates the medical 39 condition of a pregnant woman as to necessitate the 40 immediate abortion of her pregnancy to avert the death of 41 the pregnant woman or for which a delay will create a 42 SJR 23 3 serious risk of substantial and irreversible physical 43 impairment of a major bodily function of the pregnant woman |
| Puberty-blocking drugs", gonadotropin-releasing hormone analogues or 42 other synthetic drugs used to stop luteinizing hormone secretion and follicle-stimulating 43 hormone secretion, synthetic antiandrogen drugs to block the androgen receptor, or any 44 other drug used to delay or suppress pubertal development in children for the purpose 45 of assisting an individual with a gender transition | Puberty-blocking drugs", gonadotropin-releasing 45 hormone analogues or other synthetic drugs used to stop 46 luteinizing hormone secretion and follicle stimulating 47 hormone secretion, synthetic antiandrogen drugs to block the 48 androgen receptor, or any other drug used to delay or 49 suppress pubertal development in children for the purpose of 50 assisting an individual with a gender transition |